Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity was posted on August 4, 2013. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

T-Spot Tuberculosis (TB) Lab Testing

Closed
PR62790Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

Agency

N/A

NAICS

541711 - Research and Development in Biotechnology

Place of Performance

At the contractor's facility, Malborough, MA, USA

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts2 people available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Teri Routh-MurphyContracting Officer

Full Description

Show more
NOTICE OF INTENT TO SOLE SOURCE: The Centers for Disease Control and Prevention (CDC) announces its intention to negotiate a sole source award with the Oxford Immunotec, Marlborough, MA. CDC has an on-going study to compare the Tuberculin skin testing (TST) to Interferon-gamma release assays (IGRA). The Tuberculosis Elimination Study Constortium (TBESC)'s two main study objectives are to evaluate and compare the performance of TSTs and IGRAs in (1) diagnosing latent TB Infection (LTBI); and, (2) predicting progression from LTBI to TB Disease including subgroups of patients. As part of this study, different IGRAs will be employed. Both QuantiFERON TB Gold In-Tube (QFT-G In-Tube) as well as T-SPOT TB. The purpose of this requirement is to add 6,604 T-SPOT TB tests Tests to the current Contract 200-2012-52749 for the remaining six (6) option period of 12 months each. The period of performance for this contract: September 29, 2012 - September 28, 2019. Oxford Immunotec is the sole proprietor of the T-SPOT TB and is also FDA Approved. Therefore, CDC intends to negotiate this requirement with Oxford Immunotec under the authority of FAR 6.302-1 and HHSAR 306.302-1, Only One Responsible Source, and 41 U.S.C. 253(c)(1). This notice of intent is not a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. All responses should be received by the August 18, 2013, at 8 AM, Eastern Standard Time (EST). All responses must be in writing and can be sent via email to hrb5@cdc.gov or faxed to 770-488-2868. No phone calls will be accepted.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS